- Главная
- Разное
- Дизайн
- Бизнес и предпринимательство
- Аналитика
- Образование
- Развлечения
- Красота и здоровье
- Финансы
- Государство
- Путешествия
- Спорт
- Недвижимость
- Армия
- Графика
- Культурология
- Еда и кулинария
- Лингвистика
- Английский язык
- Астрономия
- Алгебра
- Биология
- География
- Детские презентации
- Информатика
- История
- Литература
- Маркетинг
- Математика
- Медицина
- Менеджмент
- Музыка
- МХК
- Немецкий язык
- ОБЖ
- Обществознание
- Окружающий мир
- Педагогика
- Русский язык
- Технология
- Физика
- Философия
- Химия
- Шаблоны, картинки для презентаций
- Экология
- Экономика
- Юриспруденция
3 Stocks Crushed by the Market This Week презентация
Содержание
- 1. 3 Stocks Crushed by the Market This Week
- 2. Plenty of health-care stocks enjoyed big gains
- 3. Shares of the 3-D bioprinting company dropped
- 4. Organovo announced financial results for fiscal 2014
- 5. The stock of the biotech fell 11%
- 6. An online post on June 10 speculated
- 7. The biopharmaceutical company’s shares dropped 10% for
- 8. Orexigen announced on Wednesday that the FDA
- 9. Organovo’s potential still is intriguing and Inovio
- 10. Find out which stock The Motley Fool’s
Plenty of health-care stocks enjoyed big gains this week. But not all of them. Here are three that were hammered pretty hard. 1 2 3
Слайд 2Plenty of health-care stocks enjoyed big gains this week. But not
all of them. Here are three that were hammered pretty hard.
1
2
3
Слайд 3Shares of the 3-D bioprinting company dropped nearly 12% this week.
Organovo Holdings (NYSEMKT:ONVO)
Source: Yahoo! Finance
Слайд 4Organovo announced financial results for fiscal 2014 on Thursday
While the results
weren’t great – miniscule revenue and increasing expenses, it’s unlikely that any observer expected any significant positive developments yet on the financial front
The focus for Organovo continues to be future-oriented, especially with the upcoming unveiling of its 3-D liver assay test
The focus for Organovo continues to be future-oriented, especially with the upcoming unveiling of its 3-D liver assay test
Why Organovo’s stock was 3-D: down, down, down
Слайд 5The stock of the biotech fell 11% this week.
Inovio Pharmaceuticals
(NYSEMKT:INO)
Source: Yahoo! Finance
Слайд 6An online post on June 10 speculated that Inovio’s CEO Joseph
Kim was laying the groundwork for announcing negative news about a phase 2 study of cervical dysplasia vaccine VGX-3100
Inovio responded publicly the next day, calling the article “false and misleading” and “inane conjecture”
The company stated that the data from the phase 2 study remains blinded and plans to report results from the phase 2 study by the end of July
Inovio responded publicly the next day, calling the article “false and misleading” and “inane conjecture”
The company stated that the data from the phase 2 study remains blinded and plans to report results from the phase 2 study by the end of July
Why the market said “no, no” to Inovio
Слайд 7The biopharmaceutical company’s shares dropped 10% for the week.
Orexigen Therapeutics
(NASDAQ:OREX)
Source: Yahoo! Finance
Слайд 8Orexigen announced on Wednesday that the FDA delayed a decision on
weight loss drug NB32 by three months, with a new PDUFA date of Sept. 11
Why the pushback? The FDA indicated that more time is needed to finalize Orexigen’s post-marketing obligations
The main issue relates to evaluation of cardiovascular outcomes
Orexigen has an ongoing study involving 8,900 patients focusing on these cardiovascular outcomes
Why the pushback? The FDA indicated that more time is needed to finalize Orexigen’s post-marketing obligations
The main issue relates to evaluation of cardiovascular outcomes
Orexigen has an ongoing study involving 8,900 patients focusing on these cardiovascular outcomes
Why Orexigen’s share price was slimmed down
Слайд 9Organovo’s potential still is intriguing and Inovio could confound critics by
reporting positive results for its DNA vaccine
The nod for best chance of rebounding, though, goes to Orexigen
While the FDA’s delay for a decision on NB32 was disappointing, the prospects for approval likely won’t be impacted
For investors who expect that NB32 will achieve greater success than earlier rivals, this week’s pullback could represent a good buying opportunity
The nod for best chance of rebounding, though, goes to Orexigen
While the FDA’s delay for a decision on NB32 was disappointing, the prospects for approval likely won’t be impacted
For investors who expect that NB32 will achieve greater success than earlier rivals, this week’s pullback could represent a good buying opportunity
Best shot at bouncing back?
?
Слайд 10Find out which stock The Motley Fool’s chief investment officer selected
as the top pick for 2014 in our free report!
